Mark Waldron1,2, Stephen David Patterson3, Jamie Tallent3, Owen Jeffries3. 1. School of Health, Sport and Applied Sciences, St Mary's University, London, TW1 4SX, UK. mark.waldron@stmarys.ac.uk. 2. School of Science and Technology, University of New England, Armidale, NSW, 2350, Australia. mark.waldron@stmarys.ac.uk. 3. School of Health, Sport and Applied Sciences, St Mary's University, London, TW1 4SX, UK.
Abstract
PURPOSE OF REVIEW: The aims of this meta-analysis were to investigate the effects of orally administered isolated taurine on resting systolic blood pressure (SBP) and diastolic blood pressure (DBP) in humans. RECENT FINDINGS: There is growing evidence that taurine deficiency is associated with hypertension and that oral supplementation can have antihypertensive effects in humans. However, these investigations have been conducted across a number of decades and populations and have not been collectively reviewed. A search was performed using various databases in May 2018 and later screened using search criteria for eligibility. There were seven peer-reviewed studies meeting the inclusion criteria, encompassing 103 participants of varying age and health statuses. Taurine ingestion reduced SBP (Hedges' g = - 0.70, 95% CI - 0.98 to - 0.41, P < 0.0001) and DBP (Hedges' g = - 0.62, 95% CI - 0.91 to - 0.34, P < 0.0001). These results translated to mean ~ 3 mmHg reductions in both SBP (range = 0-15 mmHg) and DBP (range = 0-7 mmHg) following a range of doses (1 to 6 g/day) and supplementation periods (1 day to 12 weeks), with no adverse events reported. These preliminary findings suggest that ingestion of taurine at the stated doses and supplementation periods can reduce blood pressure to a clinically relevant magnitude, without any adverse side effects. Future studies are needed to establish the effects of oral taurine supplementation on targeted pathologies and the optimal supplementation doses and periods.
PURPOSE OF REVIEW: The aims of this meta-analysis were to investigate the effects of orally administered isolated taurine on resting systolic blood pressure (SBP) and diastolic blood pressure (DBP) in humans. RECENT FINDINGS: There is growing evidence that taurine deficiency is associated with hypertension and that oral supplementation can have antihypertensive effects in humans. However, these investigations have been conducted across a number of decades and populations and have not been collectively reviewed. A search was performed using various databases in May 2018 and later screened using search criteria for eligibility. There were seven peer-reviewed studies meeting the inclusion criteria, encompassing 103 participants of varying age and health statuses. Taurine ingestion reduced SBP (Hedges' g = - 0.70, 95% CI - 0.98 to - 0.41, P < 0.0001) and DBP (Hedges' g = - 0.62, 95% CI - 0.91 to - 0.34, P < 0.0001). These results translated to mean ~ 3 mmHg reductions in both SBP (range = 0-15 mmHg) and DBP (range = 0-7 mmHg) following a range of doses (1 to 6 g/day) and supplementation periods (1 day to 12 weeks), with no adverse events reported. These preliminary findings suggest that ingestion of taurine at the stated doses and supplementation periods can reduce blood pressure to a clinically relevant magnitude, without any adverse side effects. Future studies are needed to establish the effects of oral taurine supplementation on targeted pathologies and the optimal supplementation doses and periods.
Authors: Michael A Moloney; Rowan G Casey; David H O'Donnell; Patricia Fitzgerald; Chris Thompson; David J Bouchier-Hayes Journal: Diab Vasc Dis Res Date: 2010-07-28 Impact factor: 3.291
Authors: F Franconi; F Bennardini; A Mattana; M Miceli; M Ciuti; M Mian; A Gironi; R Anichini; G Seghieri Journal: Am J Clin Nutr Date: 1995-05 Impact factor: 7.045
Authors: R Schwarzer; D Kivaranovic; M Mandorfer; R Paternostro; D Wolrab; B Heinisch; T Reiberger; M Ferlitsch; C Gerner; M Trauner; M Peck-Radosavljevic; A Ferlitsch Journal: Aliment Pharmacol Ther Date: 2017-11-03 Impact factor: 8.171
Authors: Robert N Peck; Luke R Smart; Rita Beier; Anthony C Liwa; Heiner Grosskurth; Daniel W Fitzgerald; Bernhard M W Schmidt Journal: BMC Nephrol Date: 2013-09-26 Impact factor: 2.388
Authors: Rachel Gibson; Chung-Ho E Lau; Ruey Leng Loo; Timothy M D Ebbels; Elena Chekmeneva; Alan R Dyer; Katsuyuki Miura; Hirotsugu Ueshima; Liancheng Zhao; Martha L Daviglus; Jeremiah Stamler; Linda Van Horn; Paul Elliott; Elaine Holmes; Queenie Chan Journal: Am J Clin Nutr Date: 2020-02-01 Impact factor: 7.045